Clinical Trial: A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

Brief Summary:

To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6 months.

Secondary Outcome

Secondary objectives are:

  1. To evaluate the early effect of Rho kinase Inhibitor (AR-12286) in reducing intraocular pressure (IOP).
  2. To evaluate the long term effect of the drug on IOP.
  3. To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.

Detailed Summary:
Sponsor: New York Glaucoma Research Institute

Current Primary Outcome: Long Lasting effect of study drug to reduce IOP [ Time Frame: 6 Months ]

To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with CACG treated for 6 months.


Original Primary Outcome: Same as current

Current Secondary Outcome: Secondary Outcome [ Time Frame: 6 Months ]

To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.


Original Secondary Outcome: Same as current

Information By: New York Glaucoma Research Institute

Dates:
Date Received: May 23, 2014
Date Started: May 2014
Date Completion:
Last Updated: April 23, 2015
Last Verified: April 2015